Technology transfer

EQS-News: Biotest AG increased sales by 32% in the financial year 2023

Retrieved on: 
Wednesday, April 10, 2024
Primary immunodeficiency, PLI, Tax, EBT, Growth, Biologics license application, Dreieich, Partnership, Patient, Research, Grifols, Management, Technology transfer, Disclosure, PID, Annual report, Next Level, S.A, Birth, FDA, BLA, Fibrinogen, Factor

In the financial year 2023, the Biotest Group generated revenue of € 684.6 million compared with € 516.1 million in the previous year.

Key Points: 
  • In the financial year 2023, the Biotest Group generated revenue of € 684.6 million compared with € 516.1 million in the previous year.
  • The consolidated EBIT result in the 2023 financial year of € 143.5 million improved considerably compared with € -16.6 million in the previous year.
  • In September 2023, Biotest reached an important milestone in the marketing authorisation process for Yimmugo® in the USA.
  • The 2023 Annual Report and the 2023 Sustainability Report are available on the company's website.

APEL Biomedical Technology Innovation and Translational Commercial Laboratory Officially Opens

Retrieved on: 
Wednesday, March 13, 2024
Yee, New Territories, Nutrition, Health, Technology transfer, Quality of life, HKSAR, Hygiene, QPP, Corporation, Certification, Environment, Innovation, Biotechnology, Partnership, Biomedical technology, Biological engineering, Translational research, Silk, Knowledge, Research, SGS, Lifestar, Translation, Science park, Sustainability, Pet, Government, Growth, Greater, Perception, PET, HKSTP, APEL, Life, Hong Kong Science Park, Toxicology, Division, Medical imaging

Dr. Grace Lau, Head of Institute for Translational Research of Hong Kong Science and Technology Parks Corporation (HKSTP) stated, "It is great to see the official opening of APEL Laboratory and the successful transformation of scientific research and technology into commercial products.

Key Points: 
  • Dr. Grace Lau, Head of Institute for Translational Research of Hong Kong Science and Technology Parks Corporation (HKSTP) stated, "It is great to see the official opening of APEL Laboratory and the successful transformation of scientific research and technology into commercial products.
  • We have attracted numerous biomedical innovation and technology enterprises, covering areas such as pharmaceuticals, medical devices, diagnostics, and traditional Chinese medicine.
  • Today, we are delighted to have officially established our presence in Hong Kong Science Park with the opening of the Biomedical Technology Innovation and Translational Commercial Laboratory.
  • The pet industry ecosystem is vibrant, and today, during the inauguration ceremony of the APEL Biomedical Technology Innovation and Translational Commercial Laboratory, APEL also organized a panel discussion on the future opportunities and transformations in the pet industry.

Sustainable Green Team, Ltd. (SGTM) Signs Letter-of-Intent with Caribbean Partner to Expand Its Global Presence in 4 Caribbean Islands

Retrieved on: 
Tuesday, April 9, 2024
Knowledge, Regeneration, XLR8, Green Team, Sale, Technology transfer, OTCQX, LOI, Soil, Marketing, Commercial property

Under the terms of the LOI, Sustainable Green Team, Ltd .

Key Points: 
  • Under the terms of the LOI, Sustainable Green Team, Ltd .
  • will grant its exclusive right to manufacture, distribute, and sell its flagship products, HUMISOIL® , XLR8®Bio , and other mutually agreed-upon products in the designated territories.
  • At the same time, the Partner will pay SGTM a revenue share or licensing fee for any products the Partner manufactures.
  • The Caribbean Partner's expertise and local presence in the designated territories will play a significant role in driving the success of this agreement."

Sustainable Green Team, Ltd. (SGTM) Signs Letter-of-Intent Expanding Their Footprint in the Northeast Region

Retrieved on: 
Thursday, March 28, 2024
Environment, Partnership, Knowledge, Climate, Lead, Green Team, Food, Technology transfer, OTCQX, LOI, Definitive, Marketing

The agreement calls for an innovative collaboration focused on manufacturing, distribution, and sales of sustainable, eco-friendly products in the Northeast United States.

Key Points: 
  • The agreement calls for an innovative collaboration focused on manufacturing, distribution, and sales of sustainable, eco-friendly products in the Northeast United States.
  • Upon entering into a Definitive Agreement, the partnership aims to revolutionize the region and expects to generate over $50 million in revenue from July 2024 to June 2027.
  • Under the terms of the LOI, Sustainable Green Team, Ltd. will take the lead in manufacturing and technology transfer for groundbreaking products like XLR8®Bio .
  • SGTM and D2E are excited about this sustainable collaboration, which will bring eco-friendly solutions to the Northeast United States.

4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

Retrieved on: 
Thursday, March 28, 2024
CDMO, Conference, TDN, Patient, Lung, Cohort, RNA, EMA, Technology transfer, Cystic fibrosis, European Medicines Agency, GMP, Clinical trial, ECFS, Safety, CFTR, AMD, Food, FDA, VG, Pharmaceutical industry

Phase 3 clinical endpoints include changes after 4D-710 treatment in ppFEV1, quality-of-life (Cystic Fibrosis Questionnaire Revised Respiratory Domain, CFQ-R-RD) and frequency of pulmonary exacerbations.

Key Points: 
  • Phase 3 clinical endpoints include changes after 4D-710 treatment in ppFEV1, quality-of-life (Cystic Fibrosis Questionnaire Revised Respiratory Domain, CFQ-R-RD) and frequency of pulmonary exacerbations.
  • The Company anticipates initiation of technology transfer to a commercial contract development and manufacturing organization (CDMO) in H1 2025.
  • Our goal is to initiate Phase 3 development in H2 2025 with 4D-710 suspension GMP process clinical trial material.
  • We look forward to sharing interim clinical data from the AEROW Phase 1/2 clinical trial at the ECFS conference in June 2024.”

AffyImmune Therapeutics Appoints Matt Britz as Chief Executive Officer and Pete Gelinas as SVP of CMC

Retrieved on: 
Tuesday, March 19, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, CALD, Control, Thyroid cancer, Growth, Bluebird bio, MAA, Drug discovery, Business, MIT, Britz, Patient, SVP, Marketing Authorisation Application, Merck, MSAT, Business development, Acquisition, CMC, Betibeglogene autotemcel, Technology transfer, Senior, MBA, CMCF, Therapy, Takeda, Equinox Group, Dana–Farber Cancer Institute, Multimedia, Chemical engineering, DFCI, Partnership, Biology, BLA, Pharmaceutical industry

AffyImmune Therapeutics, Inc ., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, announced today the appointment of Matt Britz to Chief Executive Officer and Pete Gelinas as Senior Vice President of Chemistry, Manufacturing, and Controls.

Key Points: 
  • AffyImmune Therapeutics, Inc ., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, announced today the appointment of Matt Britz to Chief Executive Officer and Pete Gelinas as Senior Vice President of Chemistry, Manufacturing, and Controls.
  • Matt is well-suited to lead AffyImmune as CEO as the Company accelerates clinical development of AIC100 in thyroid cancer, and in other indications with high unmet medical need.
  • Matt Britz joined AffyImmune in June 2021 as Senior Vice President (SVP), Business Development and was promoted to Chief Operating Officer in January 2022.
  • Pete Gelinas brings over 15 years of extensive experience in Manufacturing and CMC Product Development to AffyImmune.

Shaperon Enrolls Its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy 'Nugel'

Retrieved on: 
Monday, March 18, 2024
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Growth, Atopic dermatitis, Inflammation, Patient, EASI, Technology transfer, PDE4, IND, Patent, FDA, Steroid, JAK, Pharmaceutical industry

Shaperon, Inc. (Kosdaq: 378800), a biotechnology company developing innovative immune drugs, announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis.

Key Points: 
  • Shaperon, Inc. (Kosdaq: 378800), a biotechnology company developing innovative immune drugs, announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis.
  • Employing a rigorous double-blind, placebo-controlled methodology, the trial is anticipated to conclude by the first half of 2026.
  • Market research forecasts indicate a robust growth of over 8.7%, projecting the global atopic dermatitis market to reach $19.1 billion by 2030.
  • Nugel represents a paradigm shift in atopic dermatitis therapy as the world's first inflammation control drug targeting 'GPCR19' action.

Innovative Medicines Canada welcomes Bettina Hamelin as new President

Retrieved on: 
Tuesday, March 19, 2024
Health, Natural science, Organization, Biotechnology, Doctor of Pharmacy, Commercialization, Science, Drug discovery, COVID-19, Knowledge, Research, Technology transfer, Engineering, Ontario Genomics, EMBA, Creative, Interim, Vaccine, Innovative Medicines Canada, Pharmaceutical industry

OTTAWA, ON, March 19, 2024 /CNW/ - Innovative Medicines Canada (IMC) is pleased to announce Dr. Bettina Hamelin has been appointed as its new President, effective April 8, 2024.

Key Points: 
  • OTTAWA, ON, March 19, 2024 /CNW/ - Innovative Medicines Canada (IMC) is pleased to announce Dr. Bettina Hamelin has been appointed as its new President, effective April 8, 2024.
  • Dr. Hamelin, PharmD, EMBA, comes to IMC with over 30 years of experience in academia, industry, and not-for-profit organizations.
  • "It's an honour to advocate for an industry that continually leverages the power of science to improve the health and well-being of Canadians," said Bettina Hamelin, Incoming President of Innovative Medicines Canada.
  • Dr. Hamelin will assume the role from David Renwick, who has been Interim President of Innovative Medicines Canada since November 2023.

Smartkem Announces Technology Collaboration Agreement with the Industrial Technology Research Institute (ITRI) in Taiwan

Retrieved on: 
Monday, March 18, 2024
ITRI, EDA, Industrial Technology Research Institute, Technology transfer, OTCQB, TCA, OTFT, Television

MANCHESTER, England, March 18, 2024 /PRNewswire/ -- Smartkem (OTCQB: SMTK), the developer of a disruptive type of organic transistor that has the potential to drive a new generation of displays, today announced that it has entered into a technology collaboration agreement with the Industrial Technology Research Institute (ITRI) in Taiwan to enable product prototyping on ITRI's equipment. This collaboration is part of Smartkem's commercialization strategy to allow global display manufacturers access to foundry services using Smartkem's technology.

Key Points: 
  • Strategic agreement will accelerate ability to manufacture commercially ready products using Smartkem OTFT technology.
  • MANCHESTER, England, March 18, 2024 /PRNewswire/ -- Smartkem (OTCQB: SMTK ), the developer of a disruptive type of organic transistor that has the potential to drive a new generation of displays, today announced that it has entered into a technology collaboration agreement with the Industrial Technology Research Institute (ITRI) in Taiwan to enable product prototyping on ITRI's equipment.
  • This collaboration is part of Smartkem's commercialization strategy to allow global display manufacturers access to foundry services using Smartkem's technology.
  • This multi-year technology collaboration agreement is part of Smartkem's commercialization strategy to enable customers to prototype products on ITRI's line using Smartkem's OTFT technology before transferring to their own lines or subcontracting to a third party.

Smartkem Announces Technology Collaboration Agreement with the Industrial Technology Research Institute (ITRI) in Taiwan

Retrieved on: 
Monday, March 18, 2024
ITRI, EDA, Industrial Technology Research Institute, Technology transfer, OTCQB, TCA, OTFT, Television

MANCHESTER, England, March 18, 2024 /PRNewswire/ -- Smartkem (OTCQB: SMTK), the developer of a disruptive type of organic transistor that has the potential to drive a new generation of displays, today announced that it has entered into a technology collaboration agreement with the Industrial Technology Research Institute (ITRI) in Taiwan to enable product prototyping on ITRI's equipment. This collaboration is part of Smartkem's commercialization strategy to allow global display manufacturers access to foundry services using Smartkem's technology.

Key Points: 
  • Strategic agreement will accelerate ability to manufacture commercially ready products using Smartkem OTFT technology.
  • MANCHESTER, England, March 18, 2024 /PRNewswire/ -- Smartkem (OTCQB: SMTK ), the developer of a disruptive type of organic transistor that has the potential to drive a new generation of displays, today announced that it has entered into a technology collaboration agreement with the Industrial Technology Research Institute (ITRI) in Taiwan to enable product prototyping on ITRI's equipment.
  • This collaboration is part of Smartkem's commercialization strategy to allow global display manufacturers access to foundry services using Smartkem's technology.
  • This multi-year technology collaboration agreement is part of Smartkem's commercialization strategy to enable customers to prototype products on ITRI's line using Smartkem's OTFT technology before transferring to their own lines or subcontracting to a third party.